PL EN


Preferences help
enabled [disable] Abstract
Number of results
2020 | 139 | 2 | 246-258
Article title

The role of FAAH and MAGL inhibitors in anxiety disorders

Content
Title variants
Languages of publication
EN
Abstracts
EN
Anxiety disorders are currently one of the most common diseases in industrialized countries, showing a continuous upward trend. Classic therapy was based on GABA receptor modulation. However, numerous side effects associated with the impact on this neurotransmission led to the search for new drugs. The involvement of other messengers like serotonin, dopamine and noradrenaline in the pathophysiology of anxiety disorders, resulted in the introduction of SSRI, SNRI, TLPD and azapirones. However, these drugs are not fully effective, have many limitations and side effects, hence the problem of finding new solutions in anxiety therapy is still valid. One of new theories indicates the role of the endocannabinoid system in the diagnosis and treatment of anxiety. It is well known, that the main endogenous cannabinoids – anandamide (AEA) and 2-arachidonoglicerol (2-AG) – are metabolized by the enzymes from the serine hydrolase group: fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). This review presents a new compounds form the froup of endocannabinoid degradation inhibitors with anxiolytic activity.
Year
Volume
139
Issue
2
Pages
246-258
Physical description
Contributors
  • Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Chodzki Str., 20-093, Lublin, Poland
  • Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Chodzki Str., 20-093, Lublin, Poland
  • Chair and Department of Clinical Immunology, Medical University of Lublin, 4a Chodzki Str., 20-093, Lublin, Poland
  • Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Chodzki Str., 20-093, Lublin, Poland
  • Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Chodzki Str., 20-093, Lublin, Poland
References
  • [1] Papagianni EP, Stevenson CW. Cannabinoid Regulation of Fear and Anxiety: an Update. Curr Psychiatry Rep. 21(6) (2019) 38
  • [2] Bedse G, Bluett RJ, Patrick TA, Romness NK, Gaulden AD, Kingsley PJ, et al. Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors. Transl. Psychiatry 8(1) (2018) 92
  • [3] Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin. Neurosci 19(2) (2017) 93–107
  • [4] Chessick CA, Allen MH, Thase ME, Batista Miralha da Cunha AABC, Kapczinski F, Silva de Lima M, dos Santos Souza JJSS. Azapirones for generalized anxiety disorder. Cochrane Database of Systematic Reviews (2006) Issue 3. Art. No. CD006115
  • [5] Viveros M.P., Marco E.M., File S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav. 81(2) (2005) 331–42.
  • [6] Zakrzeska A, Grędziński T, Kisiel W, Chabielska E. Cannabinoids and haemostasis. Postepy Hig. Med. Dosw. 70(0) (2016) 760–74
  • [7] Fowler CJ. The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs—A practical view. Eur. Neuropsychopharmacol 25(6) (2015) 749–62
  • [8] Lee JLC, Bertoglio LJ, Guimarães FS, Stevenson CW. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br. J. Pharmacol. 174(19) (2017) 3242–56
  • [9] Battista N, Di Tommaso M, Bari M, Maccarrone M. The endocannabinoid system: an overview. Front Behav. Neurosci 6 (2012) 9
  • [10] Bow EW, Rimoldi JM. The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation. Perspect Medicin Chem. 8 (2016) 17–39
  • [11] Maccarrone M. Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years. Front Mol. Neurosci. 10 (2017) 166
  • [12] Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends. Pharmacol. Sci. 34(11) (2013) 637–44
  • [13] Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 153(2) (2008) 199–215
  • [14] Mallet C, Dubray C, Dualé C. FAAH inhibitors in the limelight, but regrettably. Int. J. Clin. Pharmacol. Ther. 54(07) (2016) 498–501
  • [15] Morena M, Patel S, Bains JS, Hill MN. Neurobiological Interactions Between Stress and the Endocannabinoid System. Neuropsychopharmacology. Nature Publishing Group 41(1) (2016) 80–102
  • [16] Guggenhuber S, Romo-Parra H, Bindila L, Leschik J, Lomazzo E, Remmers F, et al. Impaired 2-AG signaling in hippocampal glutamatergic neurons: Aggravation of anxiety-like behavior and unaltered seizure susceptibility. Int. J. Neuropsychopharmacol 19(2) (2016) 1–13
  • [17] Bluett RJ, Gamble-George JC, Hermanson DJ, Hartley ND, Marnett LJ, Patel S. Central anandamide deficiency predicts stress-induced anxiety: Behavioral reversal through endocannabinoid augmentation. Transl. Psychiatry 4(7) (2014) e408
  • [18] Lu Y, Anderson HD. Cannabinoid signaling in health and disease. Can. J. Physiol Pharmacol 95(4) (2017) 311–27
  • [19] Labar G, Michaux C. Fatty Acid Amide Hydrolase: From Characterization to Therapeutics. Chem. Biodivers 4(8) (2007) 1882–902
  • [20] Biernacki M, Skrzydlewska E. Metabolizm endokannabinoidów Metabolism of endocannabinoids Postepy Hig. Med. Dosw. 70(0) (2016) 830-43
  • [21] Deplano A, Cipriano M, Moraca F, Novellino E, Catalanotti B, Fowler CJ, et al. Benzylamides and piperazinoarylamides of ibuprofen as fatty acid amide hydrolase inhibitors. J. Enzyme. Inhib. Med. Chem. 34(1) (2019) 562-76
  • [22] Feledziak M, Lambert DM, Marchand-Brynaert J, Muccioli GG. Inhibitors of the endocannabinoid-degrading enzymes, or how to increase endocannabinoid’s activity by preventing their hydrolysis. Recent Pat CNS Drug Discov. 7(1) (2012) 49-70
  • [23] Kruk-Slomka M, Banaszkiewicz I, Slomka T, Biala G. Effects of Fatty Acid Amide Hydrolase Inhibitors Acute Administration on the Positive and Cognitive Symptoms of Schizophrenia in Mice. Mol. Neurobiol. 56(11) (2019) 7251-7266
  • [24] McLaughlin RJ, Gobbi G. Cannabinoids and emotionality: a neuroanatomical perspective. Neuroscience 204 (2012) 134-44
  • [25] Fidelman S, Mizrachi Zer-Aviv T, Lange R, Hillard CJ, Akirav I. Chronic treatment with URB597 ameliorates post-stress symptoms in a rat model of PTSD. Eur. Neuropsychopharmacol 28(5) (2018) 630-42
  • [26] Danandeh A, Vozella V, Lim J, Oveisi F, Ramirez GL, Mears D, et al. Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety. Psychopharmacology (Berl) 235(11) (2018) 3211-21
  • [27] Duan T, Gu N, Wang Y, Wang F, Zhu J, Fang Y, et al. Fatty acid amide hydrolase inhibitors produce rapid anti-anxiety responses through amygdala long-term depression in male rodents. J. Psychiatry Neurosci 42(4) (2017) 230-41
  • [28] Griebel G, Stemmelin J, Lopez-Grancha M, Fauchey V, Slowinski F, Pichat P, et al. The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents. Sci. Rep. 8(1) (2018) 2416
  • [29] Marco EM, Rapino C, Caprioli A, Borsini F, Laviola G, Maccarrone M. Potential Therapeutic Value of a Novel FAAH Inhibitor for the Treatment of Anxiety. PLoS One 10(9) (2015) e0137034
  • [30] Grabner GF, Zimmermann R, Schicho R, Taschler U. Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling. Pharmacology and Therapeutics 175 (2017) 35–46
  • [31] Granchi C, Caligiuri I, Bertelli E, Poli G, Rizzolio F, Macchia M, et al. Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors. J. Enzyme Inhib. Med. Chem. 32(1) (2017) 1240-52
  • [32] Granchi C, Rizzolio F, Bordoni V, Caligiuri I, Manera C, Macchia M, et al. 4-Aryliden-2-methyloxazol-5(4 H )-one as a new scaffold for selective reversible MAGL inhibitors. J. Enzyme Inhib. Med. Chem. 31(1) 2016 137-46
  • [33] Bluett RJ, Báldi R, Haymer A, Gaulden AD, Hartley ND, Parrish WP, et al. Endocannabinoid signalling modulates susceptibility to traumatic stress exposure. Nat Commun 8 (2017) 14782
  • [34] Viana TG, Bastos JR, Costa RB, Hott SC, Mansur FS, Coimbra CC, et al. Hypothalamic endocannabinoid signalling modulates aversive responses related to panic attacks. Neuropharmacology 148 (2019) 284–90
  • [35] Moreira FA, Aguiar DC, Guimarães FS. Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 52(3) (2007) 958–65
  • [36] Huang W-J, Chen W-W, Zhang X. Endocannabinoid system: Role in depression, reward and pain control (Review). Mol. Med. Rep. 14(4) (2016) 2899–903
  • [37] Fowler CJ. The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs—A practical view. Eur. Neuropsychopharmacol 25(6) (2015) 749–62
  • [38] Griebel, G. et al. Selective blockade of the hydrolysis of the endocannabinoid2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents. Sci. Rep. 5 (2015) 7642
  • [39] Malenczyk K., Jazurek M., Keimpema E., Silvestri C., Janikiewicz J., Mackie K., Di Marzo V., Redowicz M.J., Harkany T., Dobrzyn A.: CB1cannabinoid receptors couple to focal adhesion kinase to control insulin release. J. Biol. Chem. 288 (2013) 32685-32699
  • [40] Simon V., Cota D. Mechanisms in endocrinology: endocannabinoids and metabolism: past, present and future. Eur. J. Endocrinol 176(6) (2017) 309-324
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-5b47c903-e1ea-4543-b82a-5bee433ae34f
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.